IGC Pharma, Inc.
IGCAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Ascendiant Capital | maintain | Buy | Aug 26, 2026 |
| Ascendiant Capital | maintain | Buy | Jun 8, 2026 |
| Ascendiant Capital | maintain | Buy | Apr 8, 2026 |
| Ascendiant Capital | maintain | Buy | Feb 23, 2026 |
| Ascendiant Capital | maintain | Buy | Dec 9, 2025 |
| Ascendiant Capital | maintain | Buy | Aug 26, 2025 |
| Alliance Global Partners | maintain | Buy | Mar 6, 2025 |
| Ascendiant Capital | maintain | Buy | Feb 24, 2025 |
| Ascendiant Capital | maintain | Buy | Dec 5, 2024 |
| Ascendiant Capital | maintain | Buy | Sep 3, 2024 |
| Ascendiant Capital | maintain | Buy | Jul 29, 2024 |
| Ascendiant Capital | maintain | Buy | Jun 21, 2024 |
Earnings History
Next report: Feb 5, 2027 · EPS est. $-0.02| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 6, 2026 | $-0.02 | $-0.02 | $328.0K | $164.0K |
| Aug 14, 2026 | $-0.03 | $-0.02 | $265.0K | $164.0K |
| May 15, 2026 | $-0.02 | $-0.02 | $317.0K | $198.0K |
| Mar 20, 2026 | $-0.02 | $-0.02 | $246.5K | $250.0K |
| Nov 14, 2025 | $-0.02 | $-0.02 | $191.0K | $383.0K |
| Aug 19, 2025 | $-0.02 | $-0.03 | $328.0K | $326.0K |
| Jun 30, 2025 | $-0.02 | $-0.02 | $260.0K | $305.0K |
| Feb 18, 2025 | $-0.02 | $-0.03 | $257.0K | $204.0K |
News
POTOMAC, MD / ACCESS Newswire / October 13, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company advancing Alzheimer's disease therapeutics and Artificial Intelligence (AI)-enabled healthcare technologies, today announced the introduction of PRISM, a new application layer designed to bring its patent-pending MINT-AD Alzheimer's AI platform closer to real-world healthcare applications, including early Alzheimer's risk stratification, cogniti…
IGC Pharma, Inc. (NYSEAMERICAN:IGC - Get Free Report) was the recipient of a large increase in short interest during the month of September. As of September 15th, there was short interest totaling 1,072,899 shares, an increase of 48.0% from the August 31st total of 724,844 shares. Based on an average daily volume of 524,387 shares,
POTOMAC, MD / ACCESS Newswire / September 28, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company") today announced it has completed enrollment in its CALMA Phase 2 trial evaluating lead asset, IGC-AD1, for agitation in Alzheimer's dementia. Enrollment complete; final participant dosing expected to conclude in early November; topline results expected Q4 2026 CALMA achieved target enrollment with 168 participants randomized, including planned over-enrollment designed to strengthen …
Phase 2 topline readout expected in Q4 2026 following patient follow-up, database lock, and unblinding POTOMAC, MD / ACCESS Newswire / August 17, 2026 / IGC Pharma, Inc. (NYSE American:IGC), a clinical-stage biotechnology company developing therapeutics and AI-enabled tools for Alzheimer's disease, today announced financial results for the second quarter ended June 30, 2026, and provided an update on the Company's lead Alzheimer's program, IGC-AD1. During the second quarter, the Phase 2 CALMA tr…
POTOMAC, MD / ACCESS Newswire / August 11, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing treatments for Alzheimer's disease, today announced that it is strengthening its regulatory, biostatistical, artificial intelligence ("AI")-enabled data science, and strategic pharmaceutical development capabilities as IGC-AD1, the Company's lead Alzheimer's drug candidate, advances toward expected Phase 2 topline results in the fourth…